Deals Shaping The Medical Industry, October 2015
Executive Summary
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, Pharmaceuticals, and Research/Analytical Tools – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in September 2015.
You may also be interested in...
Behind A Rekindled Dream And China Biotech’s New Reality
The latest mega deals aimed at bringing Chinese innovation to the US have rekindled go-global hopes for a sector badly needing some cheer. But some investors say out-licensing may be the best route and that Chinese biotech must scale back its do-all mentality and focus on what it does best amid a new reality.
Givaudan’s AI-Powered Myrissi Allows Scents To Be Seen, Felt, Marketed
Myrissi draws on a decade of academic research in brain imagery and AI, an odor-color database of more than 25,000 consumer tests, and a wealth of affective data to translate fragrances into color patterns and images and predict the end consumer’s emotional response. The technology is targeted for use in developing fine fragrance, beauty and home-care products and marketing campaigns.
Takeda On Continued Lookout For Assets After Recent Deals
Leading Japanese firm reports solid growth in its fiscal nine months as it hints more may be to come after recent major deals to expand the mid- to late-stage pipeline and highlights progress for some key internal assets.